Tyra biosciences appoints doug warner, m.d., as chief medical officer

-dr. warner brings over twenty years of proven clinical development leadership to tyra having successfully led global development and secured approvals for medicines across oncology and skeletal disease- carlsbad, calif. , sept. 10, 2024 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, announced today the appointment of doug warner, m.d.
TYRA Ratings Summary
TYRA Quant Ranking